SCHEMBL10249422

SCHEMBL10249422

CCC(=O)N1CC(NCc2ccc3ccccc3c2)C(=O)N(CC(=O)OC)c2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 1/20 0.47
XIAP P98170 11/20 0.41
CYP3A4 P08684 5/20 0.39
MEN1 O00255 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
KMT2A Q03164 1/20 0.39
PYGL P06737 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10201705 1.00 OPRL1 (0.47) OPRL1XIAPCYP3A4MEN1CYP2D6
SCHEMBL10284666 0.92 OPRL1 (0.47) OPRL1XIAPCYP3A4MEN1CYP2D6
SCHEMBL10268080 0.92 OPRL1 (0.47) OPRL1XIAPCYP3A4MEN1CYP2D6
SCHEMBL10200487 0.81 XIAP (0.37) XIAPCYP3A4
SCHEMBL10248386 0.81 XIAP (0.37) XIAPCYP3A4
SCHEMBL10249375 0.81 XIAP (0.38) XIAPCYP3A4
SCHEMBL10201713 0.81 XIAP (0.38) XIAPCYP3A4
SCHEMBL645000 0.80 CASP1 (0.51) XIAPCYP3A4
SCHEMBL10201707 0.77 LMNA (0.41) OPRL1MEN1KMT2APYGL
SCHEMBL10249419 0.77 LMNA (0.41) OPRL1MEN1KMT2APYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119631-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-21 US disclosed
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME IL1A, IFNAR1, IL1B OPRL1 3099/4885XIAP 257/4885CYP3A4 2587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.